Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2.

Karczewski J, Spencer RH, Garsky VM, Liang A, Leitl MD, Cato MJ, Cook SP, Kane S, Urban MO.

Br J Pharmacol. 2010 Oct;161(4):950-60. doi: 10.1111/j.1476-5381.2010.00918.x.

2.

Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.

Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X.

Virology. 2009 Mar 1;385(1):218-26. doi: 10.1016/j.virol.2008.11.035. Epub 2008 Dec 13.

3.

Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion.

Herrington J, Zhou YP, Bugianesi RM, Dulski PM, Feng Y, Warren VA, Smith MM, Kohler MG, Garsky VM, Sanchez M, Wagner M, Raphaelli K, Banerjee P, Ahaghotu C, Wunderler D, Priest BT, Mehl JT, Garcia ML, McManus OB, Kaczorowski GJ, Slaughter RS.

Diabetes. 2006 Apr;55(4):1034-42. Erratum in: Diabetes. 2006 Jun;55(6):1904.

4.

Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier.

Ionescu RM, Przysiecki CT, Liang X, Garsky VM, Fan J, Wang B, Troutman R, Rippeon Y, Flanagan E, Shiver J, Shi L.

J Pharm Sci. 2006 Jan;95(1):70-9.

PMID:
16315228
5.

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW.

Vaccine. 2004 Aug 13;22(23-24):2993-3003.

PMID:
15297047
6.

Progress towards the development of a HIV-1 gp41-directed vaccine.

McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ.

Curr HIV Res. 2004 Apr;2(2):193-204. Review.

PMID:
15078183
7.

Rational design and synthesis of selective BACE-1 inhibitors.

Brady SF, Singh S, Crouthamel MC, Holloway MK, Coburn CA, Garsky VM, Bogusky M, Pennington MW, Vacca JP, Hazuda D, Lai MT.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):601-4.

PMID:
14741251
8.

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.

McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller M, Shiver J, Bogusky MJ.

Biochemistry. 2003 Mar 25;42(11):3214-23.

PMID:
12641452
9.

A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

DeFeo-Jones D, Brady SF, Feng DM, Wong BK, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Pawluczyk JM, Wai J, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A, Jones RE.

Mol Cancer Ther. 2002 May;1(7):451-9.

10.

Two tarantula peptides inhibit activation of multiple sodium channels.

Middleton RE, Warren VA, Kraus RL, Hwang JC, Liu CJ, Dai G, Brochu RM, Kohler MG, Gao YD, Garsky VM, Bogusky MJ, Mehl JT, Cohen CJ, Smith MM.

Biochemistry. 2002 Dec 17;41(50):14734-47.

PMID:
12475222
11.

Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.

Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM.

J Med Chem. 2002 Oct 10;45(21):4706-15.

PMID:
12361397
12.

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, Danzeisen RC, Miller MD, Shiver JW, Keller PM.

J Biol Chem. 2002 Nov 29;277(48):45811-20. Epub 2002 Sep 16. Erratum in: J Biol Chem. 2003 Feb 14;278(7):5492..

13.

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM.

J Med Chem. 2001 Nov 22;44(24):4216-24.

PMID:
11708923
14.

Thermodynamics of peptide inhibitor binding to HIV-1 gp41.

Cole JL, Garsky VM.

Biochemistry. 2001 May 15;40(19):5633-41.

PMID:
11341828
15.

The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.

Shi XP, Chen E, Yin KC, Na S, Garsky VM, Lai MT, Li YM, Platchek M, Register RB, Sardana MK, Tang MJ, Thiebeau J, Wood T, Shafer JA, Gardell SJ.

J Biol Chem. 2001 Mar 30;276(13):10366-73.

16.

PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, Lin JH.

Drug Metab Dispos. 2001 Mar;29(3):313-8.

PMID:
11181501
17.

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.

DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE.

Nat Med. 2000 Nov;6(11):1248-52.

PMID:
11062536
19.

Structural studies on phospholamban and implications for regulation of the Ca(2+)-ATPase.

Mortishire-Smith RJ, Broughton H, Garsky VM, Mayer EJ, Johnson RG Jr.

Ann N Y Acad Sci. 1998 Sep 16;853:63-78.

PMID:
10603937
20.

Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase.

Bogusky MJ, Culberson JC, Pitzenberger SM, Garsky VM, Wallace A, Pessi A, Koblan KS.

J Pept Res. 1999 Jul;54(1):66-73.

PMID:
10448971
21.

Selective inhibition of factor Xa in the prothrombinase complex by the carboxyl-terminal domain of antistasin.

Mao SS, Przysiecki CT, Krueger JA, Cooper CM, Lewis SD, Joyce J, Lellis C, Garsky VM, Sardana M, Shafer JA.

J Biol Chem. 1998 Nov 13;273(46):30086-91.

23.

Biochemical and biophysical comparison of native and chemically synthesized phospholamban and a monomeric phospholamban analog.

Mayer EJ, McKenna E, Garsky VM, Burke CJ, Mach H, Middaugh CR, Sardana M, Smith JS, Johnson RG Jr.

J Biol Chem. 1996 Jan 19;271(3):1669-77.

24.

Solution structure of the cytoplasmic domain of phopholamban: phosphorylation leads to a local perturbation in secondary structure.

Mortishire-Smith RJ, Pitzenberger SM, Burke CJ, Middaugh CR, Garsky VM, Johnson RG.

Biochemistry. 1995 Jun 13;34(23):7603-13.

PMID:
7779806
25.

Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa.

Mao SS, Huang J, Welebob C, Neeper MP, Garsky VM, Shafer JA.

Biochemistry. 1995 Apr 18;34(15):5098-103.

PMID:
7711029
26.

Three-dimensional structure of echistatin and dynamics of the active site.

Chen Y, Suri AK, Kominos D, Sanyal G, Naylor AM, Pitzenberger SM, Garsky VM, Levy RM, Baum J.

J Biomol NMR. 1994 May;4(3):307-24.

PMID:
8019139
27.

Development of 1,4-benzodiazepine cholecystokinin type B antagonists.

Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Garsky VM, Gilbert KF, Leighton JL, Carson KL, Mellin EC, et al.

J Med Chem. 1993 Dec 24;36(26):4276-92.

PMID:
8277510
28.

Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M.

Endocrinology. 1993 Mar;132(3):1411-3.

PMID:
8440195
29.

Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1993 Feb;13(2):953-60.

30.

Site-directed analysis of the functional domains in the factor Xa inhibitor tick anticoagulant peptide: identification of two distinct regions that constitute the enzyme recognition sites.

Dunwiddie CT, Neeper MP, Nutt EM, Waxman L, Smith DE, Hofmann KJ, Lumma PK, Garsky VM, Vlasuk GP.

Biochemistry. 1992 Dec 8;31(48):12126-31. Erratum in: Biochemistry 1993 Mar 30;32(12):3196.

PMID:
1457408
31.

Invertebrate aspartyl/asparaginyl beta-hydroxylase: potential modification of endogenous epidermal growth factor-like modules.

Monkovic DD, VanDusen WJ, Petroski CJ, Garsky VM, Sardana MK, Zavodszky P, Stern AM, Friedman PA.

Biochem Biophys Res Commun. 1992 Nov 30;189(1):233-41.

PMID:
1449478
32.

Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.

Williams PD, Bock MG, Tung RD, Garsky VM, Perlow DS, Erb JM, Lundell GF, Gould NP, Whitter WL, Hoffman JB, et al.

J Med Chem. 1992 Oct 16;35(21):3905-18.

PMID:
1331448
33.

Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.

Stirdivant SM, Huber HE, Patrick DR, Defeo-Jones D, McAvoy EM, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1992 May;12(5):1905-14.

35.

Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein.

Jones RE, Heimbrook DC, Huber HE, Wegrzyn RJ, Rotberg NS, Stauffer KJ, Lumma PK, Garsky VM, Oliff A.

J Biol Chem. 1992 Jan 15;267(2):908-12.

36.

Proton NMR assignments and secondary structure of the snake venom protein echistatin.

Chen Y, Pitzenberger SM, Garsky VM, Lumma PK, Sanyal G, Baum J.

Biochemistry. 1991 Dec 17;30(50):11625-36.

PMID:
1661142
37.

Sequence dependence of protein isoprenylation.

Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL, Gibbs JB.

J Biol Chem. 1991 Aug 5;266(22):14603-10.

38.

Bovine liver aspartyl beta-hydroxylase. Purification and characterization.

Wang QP, VanDusen WJ, Petroski CJ, Garsky VM, Stern AM, Friedman PA.

J Biol Chem. 1991 Jul 25;266(21):14004-10.

39.

The bovine endothelin receptor has an apparent molecular weight of 43,000.

Bednar DL, Stein RB, Garsky VM, Williams DL Jr.

Biochim Biophys Acta. 1991 Apr 17;1092(2):226-32.

PMID:
1850303
41.
42.

Echistatin is a potent inhibitor of bone resorption in culture.

Sato M, Sardana MK, Grasser WA, Garsky VM, Murray JM, Gould RJ.

J Cell Biol. 1990 Oct;111(4):1713-23.

43.

Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase.

Schaber MD, O'Hara MB, Garsky VM, Mosser SC, Bergstrom JD, Moores SL, Marshall MS, Friedman PA, Dixon RA, Gibbs JB.

J Biol Chem. 1990 Sep 5;265(25):14701-4.

44.

Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein.

Jones RE, Wegrzyn RJ, Patrick DR, Balishin NL, Vuocolo GA, Riemen MW, Defeo-Jones D, Garsky VM, Heimbrook DC, Oliff A.

J Biol Chem. 1990 Aug 5;265(22):12782-5.

45.

Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.

Freidinger RM, Williams PD, Tung RD, Bock MG, Pettibone DJ, Clineschmidt BV, DiPardo RM, Erb JM, Garsky VM, Gould NP, et al.

J Med Chem. 1990 Jul;33(7):1843-5. No abstract available.

PMID:
2163451
46.

Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro.

Cordingley MG, Callahan PL, Sardana VV, Garsky VM, Colonno RJ.

J Biol Chem. 1990 Jun 5;265(16):9062-5.

47.

Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.

Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA.

J Biol Chem. 1990 May 25;265(15):8558-65.

48.

Structure/function relationships of ras and guanosine triphosphatase-activating protein.

Gibbs JB, Schaber MD, Garsky VM, Vogel US, Scolnick EM, Dixon RA, Marshall MS.

Soc Gen Physiol Ser. 1990;45:77-85. Review. No abstract available.

PMID:
2198666
49.

Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli.

Cordingley MG, Register RB, Callahan PL, Garsky VM, Colonno RJ.

J Virol. 1989 Dec;63(12):5037-45.

50.

Affinity purification of the HIV-1 protease.

Heimbach JC, Garsky VM, Michelson SR, Dixon RA, Sigal IS, Darke PL.

Biochem Biophys Res Commun. 1989 Nov 15;164(3):955-60.

PMID:
2686642

Supplemental Content

Loading ...
Support Center